How rare is Thomsen and Becker disease?

Thomsen and Becker disease is classified as uncommon. The estimated prevalence is approximately 1-9 in 100,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

How is Thomsen and Becker disease diagnosed?

Information about diagnosis is currently limited for this condition.

Are there treatments for Thomsen and Becker disease?

Information about treatment is currently limited for this condition.

What complications can arise from Thomsen and Becker disease?

Thomsen and Becker disease can lead to complications related to muscle stiffness and myotonia. This may affect daily activities, making it harder to perform tasks that require quick muscle relaxation. However, specific complications and their management are not well-documented.

How does Thomsen and Becker disease affect daily life?

Living with Thomsen and Becker disease can be challenging due to muscle stiffness and slow relaxation after contractions. This may make activities like walking, climbing stairs, or even holding objects more difficult. It's important for individuals to find ways to manage these symptoms in their daily routines.

What is the life expectancy for someone with Thomsen and Becker disease?

Currently, there is limited information about the life expectancy of individuals with Thomsen and Becker disease. Because this condition affects muscle function, it may impact overall health, but specific data on longevity is not available. Regular check-ups with healthcare providers can help monitor health.

Are there any specialists I should see for Thomsen and Becker disease?

While specific specialist recommendations for Thomsen and Becker disease are not provided, seeing a neurologist or a specialist in muscle disorders may be beneficial. These professionals can help manage symptoms and provide support tailored to the needs of individuals with this condition.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Thomsen and Becker disease - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

Thomsen and Becker disease

MONDO:0009710

Also known as:myotonia congenitaBatten-Turner congenital myopathymyopathy, congenital

Find Clinical TrialsTrials

Overview

A rare, genetic, skeletal muscle channelopathy characterized by slow muscle relaxation after contraction (myotonia).

Clinical Trials3 registered · 2 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

GeneReviews

Clinical Guidance

Myotonia congenita is characterized by muscle stiffness present from childhood; all striated muscle groups including the extrinsic eye muscles, facial muscles, and tongue may be involved. Stiffness is relieved by repeated contractions of the muscle (the "warm-up" phenomenon). Muscles are usually hypertrophic. Whereas autosomal recessive (AR) myotonia congenita is often associated with more severe manifestations (such as progressive, minor distal weakness and attacks of transient weakness brought on by movement after rest), autosomal dominant (AD) myotonia congenita is not. A study of more than 300 affected individuals from the UK revealed a ratio of 70% AR myotonia congenita to 30% AD myotonia congenita among families with a molecularly confirmed diagnosis . Comparable distribution has been identified in Italian , Spanish , and German cohorts ; in contrast, AD myotonia congenita is more common than AR myotonia congenita in Denmark . Table 2. Myotonia Congenita: Comparison of Select Features by Mode of Inheritance

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

No consensus clinical diagnostic criteria for myotonia congenita (sometimes referred to as "chloride channel myotonia") have been published.

Suggestive Findings

Myotonia congenita should be suspected in individuals with the following clinical and laboratory findings.

Clinical findings and medical history

Episodes of muscle stiffness (myotonia) or cramps beginning in early childhood

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for Thomsen and Becker disease. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

No specific clinical practice guidelines for myotonia congenita have been published. However, a general guideline on clinical presentation and management of nondystrophic myotonias is available .

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with myotonia congenita, the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:

Prognosis

Estimated prevalence: 1-9 in 100,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

3 clinical trials registered, 2 recruiting. Interventions under study include other interventions and medical devices. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.

57 publications have been identified in PubMed for Thomsen and Becker disease. Research spans Case Report / Case Series (40%), Basic Science / Preclinical (33%), and Review / Meta-Analysis (12%).

Research Type	Count	% of Total
Patient case studies	23

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:49 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:614

GARD

Genetic and Rare Diseases Info Center

GARD:12301

Questions for Your Care Team

→Are any of the 3 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about Thomsen and Becker disease

Thomsen and Becker disease, also known as myotonia congenita or Batten-Turner congenital myopathy, is a rare genetic condition affecting the skeletal muscles. It is marked by slow muscle relaxation after a contraction, a feature known as myotonia. This condition falls under the category of muscle channelopathies, meaning it involves an abnormality in the muscle cell channels that regulate contraction and relaxation. Information about other aspects of this condition is currently limited.

People with this condition typically experience muscle stiffness due to slow muscle relaxation after voluntary contractions. This key symptom of myotonia is the main sign of the condition.

Thomsen and Becker disease is a genetic disorder. It is caused by changes in the genes that affect the function of muscle cell channels. Detailed genetic causes and risk factors are not provided in the current sources. Associated genes include CLCN1.

← Back to All Diseases

Feature	AR Myotonia Congenita	AD Myotonia Congenita
Age of onset	Early childhood	Early infancy
Muscle stiffness	Generalized, legsarms	Generalized, armslegs
Muscle hypertrophy	Generalized	Generalized
Pain	Very common	Common
Transient muscle weakness	Common	Not present
Distal muscle weakness	Rarely	Not present
Proximal muscle weakness	Rarely	Not present Age of onset is variable. In AD myotonia congenita, onset of symptoms is usually in infancy or early childhood. In AR myotonia congenita, the average age of onset is slightly older. In both conditions, onset may be as late as the third or fourth decade of life.

Kisho

Thomsen and Becker disease

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Evaluations Following Initial Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Differential Diagnosis

Treatment of Manifestations

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Recent Publications

Thomsen and Becker disease

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Evaluations Following Initial Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is Thomsen and Becker disease?

What are the symptoms of Thomsen and Becker disease?

What causes Thomsen and Becker disease?

How rare is Thomsen and Becker disease?

How is Thomsen and Becker disease diagnosed?

Are there treatments for Thomsen and Becker disease?

What complications can arise from Thomsen and Becker disease?

How does Thomsen and Becker disease affect daily life?

What is the life expectancy for someone with Thomsen and Becker disease?

Are there any specialists I should see for Thomsen and Becker disease?

Differential Diagnosis

Treatment of Manifestations

Clinical Guidance

Therapies Under Investigation

Clinical Trials

Recent Publications